Clinical Trials for Colon Cancer

An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, progressive advanced solid tumors and no suitable standard therapy receive GV20-0251 alone or with pembrolizumab; expansion cohorts focus on selected tumor types, including melanoma, NSCLC, head and neck and endometrial cancers, and pMMR/MSS colorectal cancer in combination cohorts. GV20-0251 is an investigational antibody targeting IGSF8, a proposed innate immune checkpoint.

ClinicalTrials.gov ID: NCT05669430

Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A Pilot Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors who developed IL-17–mediated immune-related adverse events after immunotherapy and require systemic steroids, testing brodalumab (an IL-17 receptor A inhibitor) as a potential steroid-sparing treatment for irAEs. Patients receive subcutaneous brodalumab alongside a planned steroid taper.

ClinicalTrials.gov ID: NCT06673329

A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, refractory solid tumors and an injectable lesion receive intratumoral CAdVEC alone or followed by autologous HER2-specific CAR T cells; HER2 positivity is required only for the combination cohorts. CAdVEC is an oncolytic adenovirus designed to destroy tumor cells and deliver IL-12, PD-L1 blockade, and a safety switch.

ClinicalTrials.gov ID: NCT03740256

A First-in-Human (FIH), Open-Label, Phase Ia/Ib Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-DP in Participants With Relapsed/Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed or refractory advanced/metastatic solid tumors who have exhausted or cannot tolerate standard therapy receive intravenous SON-DP once or twice weekly; expansion cohorts are limited to breast, pancreatic, ovarian, and colorectal cancers. SON-DP is an investigational transcription-factor protein intended to reprogram cancer cells toward a noncancerous state, a mechanism not yet clinically established.

ClinicalTrials.gov ID: NCT05989724

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors and ECOG 0–1 receive GI-102 alone or with selected anticancer agents; a dose-optimization cohort focuses on checkpoint inhibitor–refractory metastatic melanoma after at least one prior line of therapy. GI-102 is an investigational CD80–IL-2 variant fusion protein designed to block CTLA-4 signaling and stimulate CD8 T and natural killer cells; combination partners include doxorubicin, paclitaxel/bevacizumab, eribulin, pembrolizumab, and trastuzumab deruxtecan.

ClinicalTrials.gov ID: NCT05824975

A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembrolizumab

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors that progressed after at least 3 months of pembrolizumab, and who have no effective treatment options, receive oral PLN-101095 alone or with continued pembrolizumab. PLN-101095 inhibits αvβ8 and αvβ1 integrins to reduce activation of immunosuppressive TGF-β in the tumor microenvironment.

ClinicalTrials.gov ID: NCT06270706

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination With Pembrolizumab, Cetuximab or FOLFIRI Plus Cetuximab in Patients With Advanced Solid Refractory/Resistant Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic refractory/resistant solid tumors, including selected colorectal, head and neck, lung, breast, renal, and acral melanoma cohorts, receive TTX-080, an investigational HLA-G–blocking antibody, alone or with pembrolizumab, cetuximab, or FOLFIRI plus cetuximab. A colorectal cancer cohort compares FOLFIRI plus cetuximab with or without TTX-080.

ClinicalTrials.gov ID: NCT04485013

Phase 1/1B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, unresectable or metastatic HER2-expressing or HER2-amplified solid tumors receive trastuzumab deruxtecan, a HER2-directed antibody–drug conjugate carrying a topoisomerase I inhibitor, plus the oral ATR inhibitor ceralasertib. Expansion cohorts are limited to patients with gastroesophageal or colorectal cancer and a biopsiable lesion.

ClinicalTrials.gov ID: NCT04704661

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic non-CNS solid tumors and a BRCA1/2 or other specified homologous-recombination repair alteration receive the investigational oral PARG inhibitor IDE161 alone after progression on or intolerance to standard therapy. A separate cohort with recurrent or advanced endometrial cancer progressing after anti-PD-1/PD-L1 therapy receives IDE161 plus pembrolizumab.

ClinicalTrials.gov ID: NCT05787587

An Open-label, Phase I Study to Assess the Safety of Multiple Doses of CYAD-101, Administered After Standard FOLFOX or FOLFIRI Chemotherapy in Patients With Unresectable Metastatic Colorectal Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, unresectable metastatic colorectal adenocarcinoma that has progressed after at least one line of therapy for metastatic disease receive multiple infusions of CYAD-101 after FOLFOX or FOLFIRI chemotherapy. CYAD-101 is a donor-derived CAR T-cell therapy targeting stress-induced NKG2D ligands, including MICA, MICB, and ULBP; its development program was discontinued in 2022.

ClinicalTrials.gov ID: NCT03692429